AURA
Aura Biosciences, Inc.
Last earnings -2.5% on 2026-05-11
$7.00
▲ +2.04%$7.00▲ +13.82%
over 1Y
L $4.97EODHDH $8.90
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+2.0%
1W+0.7%
1M-8.6%
3M+11.6%
YTD+32.1%
1Y+13.8%
Avoid
Conviction
Horizon
Long (>12mo)
Street · 12 analysts
Buy
Pre-revenue clinical-stage biotech burning $85M/yr with one shot on goal — binary bel-sar outcome makes this a speculation, not an investment.
Net income -$106M · FY2025
Aura is a textbook clinical-stage biotech: zero product revenue across its entire history (FY2021–FY2025 all show '—' for revenue), an accumulated deficit of $480M, and a FY2025 net loss of $106M that widened 22% YoY. The company itself flags going-concern risk in Item 1A, stating it 'will continue to incur losses for the foreseeable future' and that R&D expense will 'increase significantly' as the global Phase 3 CoMpass trial for bel-sar progresses. R&D already jumped 23% to $90.3M in FY2025 — that is the entire P&L story. There is no business to value on fundamentals; the equity is a call option on a single molecule.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$35.3M | -$60.3M | -$85.0M | -$96.1M | -$113M |
| Net income | -$35.3M | -$58.8M | -$76.4M | -$86.9M | -$106M |
| Diluted EPS | -$8.95 | -$1.96 | -$1.93 | -$1.75 | -$1.76 |
| Net margin | — | — | — | — | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$390M
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-23.6%
FCF yield-19.0%
Quality & risk
ROIC (est.)-65.1%
Free cash flow-$85.2M
Total debt—
Net cash$59.5M
Piotroski F-Score1/6
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+27.7%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsRecent disclosure tone has skewed negative — read the flagged items.
- 8-K Shareholder vote2026-06-11
Annual meeting results disclosed (Item 5.07); routine director votes, no surprises.
- 8-K Earnings results2026-05-11
Q1'26 10-Q: still pre-revenue, R&D rising, cash burn pressures runway.
- 10-Q Quarterly report2026-05-11
Q1'26 10-Q: still pre-revenue, R&D rising, cash burn pressures runway.
- 8-K Material agreement2026-05-05
Entered new material agreement (Item 1.01); terms could affect runway/partnerships.
- 8-K Material agreement2026-05-04
Officer/director change with Reg FD disclosure; leadership transition for shareholders.
- 8-K Officer / director change2026-05-04
Officer/director change with Reg FD disclosure; leadership transition for shareholders.
- DEF 14A Proxy statement2026-04-20
2026 proxy: board slate and exec comp for shareholder vote; routine.
- 8-K Earnings results2026-03-30
FY25 10-K: -$106M loss, $480M deficit, going-concern risk flagged; cash $59.5M.
- 10-K Annual report2026-03-30
FY25 10-K: -$106M loss, $480M deficit, going-concern risk flagged; cash $59.5M.
Recent filings
all on EDGAR ↗PRE 14APeriod ending 2026-08-052026-06-17open ↗144Filing2026-06-16open ↗4Period ending 2026-06-162026-06-16open ↗4Period ending 2026-06-112026-06-15open ↗4Period ending 2026-06-112026-06-15open ↗4Period ending 2026-06-112026-06-15open ↗4Period ending 2026-06-112026-06-15open ↗8-KPeriod ending 2026-06-112026-06-11open ↗4Period ending 2026-05-192026-05-19open ↗S-8Filing2026-05-19open ↗SCHEDULE 13GFiling2026-05-12open ↗4Period ending 2026-05-072026-05-11open ↗
Frequently asked
- Is Aura Biosciences, Inc. (AURA) a buy?
- AURA currently carries a Avoid rating with 4/5 conviction, derived from its latest SEC filings. Pre-revenue clinical-stage biotech burning $85M/yr with one shot on goal — binary bel-sar outcome makes this a speculation, not an investment.
- What is Aura Biosciences, Inc.'s quality score?
- AURA scores 36.179487179487175/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001501796, latest 10-Q filed 2026-05-11) · EODHD · analysis by claude-code · as of 6/25/2026, 3:09:06 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.